Meletios Dimopoulos

1:19
Moving towards a daratumumab standard of care in MM
Meletios Dimopoulos
1:44
OPTIMISMM: benefits of a new triplet therapy for MM patients relapsing on lenalidomide
Meletios Dimopoulos
2:43
Imaging modalities and treatment breakthroughs in myeloma bone disease
Meletios Dimopoulos
1:32
iNNOVATE results: a prospective new standard of care for Waldenström’s
Meletios Dimopoulos
1:56
Randomized trials of pomalidomide combinations for MM
Meletios Dimopoulos
6:23
Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab
Meletios Dimopoulos
1:21
Highlights on interesting data presented at COMy 2017
Meletios Dimopoulos
1:31
How effective are current drug treatments for patients with myeloma kidney disease?
Meletios Dimopoulos
1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos
1:37
Which is the best combination therapy in relapsed and refractory multiple myeloma?
Meletios Dimopoulos
1:50
Which treatments are currently available for relapsed and refractory myeloma treatment?
Meletios Dimopoulos
5:36
Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX trial
Meletios Dimopoulos
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals